Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

Researchers discover novel targets for bladder cancer therapeutics and demonstrate that a new combination of existing drugs, including statins, blocks tumor growth in mice.

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with ...

Vera Therapeutics (VERA) announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein ...

(HealthDay News) — The machine learning system SCORPIO can predict patient outcomes with immune checkpoint inhibitor (ICI) therapy across diverse cancer types and health care settings, according to a ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on BMEA stock, giving a Buy rating yesterday.Stay Ahead of the ...